Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium.

In the last two decades, statin therapy has proved to be the most potent isolated therapy for attenuation of cardiovascular risk. Its frequent use has been seen as one of the most important elements for the reduction of cardiovascular mortality in developed countries. However, the recurrent incidence of muscle symptoms in statin users raised the possibility of causal association, leading to a disease entity known as statin associated muscle symptoms (SAMS). Mechanistic studies and clinical trials, specifically designed for the study of SAMS have allowed a deeper understanding of the natural history and accurate incidence. This set of information becomes essential to avoid an unnecessary risk of severe forms of SAMS. At the same time, this concrete understanding of SAMS prevents overdiagnosis and an inadequate suspension of one of the most powerful prevention strategies of our times. In this context, the Luso-Latin American Consortium gathered all available information on the subject and presents them in detail in this document as the basis for the identification and management of SAMS.

Clinical correlation between the Point-of-care testing method and the traditional clinical laboratory diagnosis in the measure of the lipid profile in patients seen in medical offices / Correlação clínica entre a metodologia Point-of-care testing e o diagnóstico laboratorial tradicional na dosagem do perfil lipídico de pacientes atendidos em consultórios médicos

ABSTRACT Introduction: Elevated plasma levels of lipids are considered the main modifiable risk factor for the cardiovascular disease. The Point-of-care testing (POCT) method provides quick results and allows anticipating diagnosis and treatment. Objective: To compare the lipid profile results obtained from both POCT and the traditional clinical laboratory. Methods: Fasting blood samples were collected from 111 patients who sought, for any reason, the private medical offices participating on this study. Capillary whole blood samples were analyzed in CardioChek® PA (CCPA) equipment, and the serum samples were analyzed in clinical laboratories (LAB) that have internal and external quality control, with certification. The mean values of each variable of the lipid profile obtained by CCPA and LAB were calculated. Linear regression was used to determine the existence of correlation between the two methods. Results: We observed a positive correlation between the values obtained by CCPA and LAB for all variables of the lipid profile. Our data, extracted from the routine use of CCPA in private medical offices, supports a substantial contribution of the POCT methodology in the detection of the main cardiovascular risk factors. Conclusion: The POCT CardioChek® PA Analyzer is an easy-to-operate tool, with adequate analytical performance and a good correlation with the results of the conventional laboratory method, therefore, considered a reliable method.

RESUMO Introdução: Níveis plasmáticos elevados de lipídios são considerados como principal fator de risco modificável para a doença cardiovascular. A metodologia Point-of-care testing (POCT) fornece resultados rápidos e permite antecipar o diagnóstico e o tratamento. Objetivo: Comparar os resultados do perfil lipídico obtidos pelo POCT e pelo laboratório convencional. Métodos: Foram coletadas amostras em jejum de 111 pacientes que procuraram, por qualquer motivo, os consultórios médicos privados participantes desta pesquisa. As amostras de sangue total da punção capilar foram analisadas no equipamento CardioChek® PA (CCPA) e as de sangue da punção venosa, coletadas e analisadas em laboratórios clínicos (LAB) que apresentam controle de qualidade interno e externo, com certificação. Os valores médios de cada variável do perfil lipídico obtidos pelo CCPA e pelo LAB foram calculados. Regressão linear foi utilizada para determinar a existência de correlação entre os dois métodos. Resultados: Observamos correlação positiva entre os valores obtidos pelo CCPA e pelo LAB para todas as variáveis do perfil lipídico. Nossos dados, extraídos do uso rotineiro do CCPA em consultórios médicos privados, suporta substancial contribuição da metodologia POCT na detecção dos principais fatores de risco cardiovascular. Conclusão: O analisador POCT CCPA configura-se como uma ferramenta de fácil operação, com performance analítica adequada e excelente correlação com os resultados do método laboratorial convencional, portanto confiáveis.

Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study.

The association of polymorphisms affecting lipid metabolism with the risk of myocardial infarction (MI) in type 2 diabetes mellitus was investigated. The Genetics, Outcomes and Lipids in type 2 Diabetes (GOLD) Study is a prospective, multicenter study, conducted on 990 patients presenting diabetes and MI (n=386), or diabetes without previous manifestation of stroke, peripheral or coronary arterial disease (n=604), recruited from 27 institutions in Brazil. APO A1 (A/G -75 and C/T +83) and APO C3 (C/G 3'UTR) non-coding sequences, CETP (Taq 1B), LPL (D9N), APO E (epsilon2, epsilon3, epsilon4,), PON-1 (Q192R), and two LCAT variants Arg(147)-->Trp and Tyr(171)-->Stop were tested by PCR-RFLP. There was a higher prevalence of LPL DN genotype (19% vs.12%, p=0.03) and a higher frequency of the N allele (11% vs. 7%) among subjects with MI when compared to controls, with an odds ratio of MI for carriers of 9N allele of 2.46 (95% CI=1.79-3.39, p<0.0001). This association was present in men and women, in non-smokers and in hypertensive patients. A logistic regression model including gender, duration of diabetes, systolic blood pressure, HDL-C, left ventricle hypertrophy and D9N polymorphism showed that the latter still remained significantly associated with MI (OR=1.50, 95% CI=1.02-2.25, p=0.049). These findings suggest that D9N polymorphism can be a useful risk marker for myocardial infarction and that further potential candidate genes should be screened for exploratory analysis and for future therapeutic intervention in diabetes.